GlassScriptPhysician profile
Mir Madani
NPI 1982611760
$8,399.33
in general payments reported to CMS, 2019-2025
36 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 79% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $1,227 · 2021: $1,504 · 2022: $1,220 · 2023: $1,152 · 2024: $1,068 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,318.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,022.38 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,011.08 | 2019-2024 | Xarelto |
| Pfizer INC. | $690.82 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $647.02 | 2021-2025 | |
| Lilly USA, LLC | $557.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.98 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $453.00 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $334.58 | 2019-2025 | Farxiga, Brilinta, Andexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $320.19 | 2019-2025 | Lifevest |
| Abiomed | $318.51 | 2021-2025 | Impella |
| Amgen INC. | $294.87 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Amarin Pharma, INC. | $290.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $260.12 | 2019-2024 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $234.44 | 2020-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $192.09 | 2022-2025 | Amvuttra |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Madani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.